Numerous studies have shown that the STAT3 signalling pathway is required for the maintenance of the stem-like malignant glioma cells and that its inhibition by either chemical inhibitors, dominant-negative mutant protein, decoy oligodeoxynucleotides, or siRNAs can be a promising therapeutic strategy [47,48,49]. Here, STAT3 is linked to central nervous system cancer.